Drug Therapy in Myasthenia Gravis and Congenital Myasthenic Syndromes

While surgical removal of the thymus gland or a thymoma is often part of the therapy of myasthenia gravis (MG), the mainstay of management for ocular MG remains drug therapy. While not every patient with MG needs medical therapy, most patients benefit from it, and it must be carefully tailored to the individual patient's overall medical situation. For the congenital myasthenic syndromes (CMS) due to genetically-determined molecular defects in the neuromuscular junction (NMJ), drug therapy can produce important improvements in motor function and quality of life.